MKIs targeting RET in addition to multiple other kinases have shown favourable activity in these thyroid cancer subtypes; however, the potency of MKI RET inhibition is limited by off-target toxicity, predominantly due to targeting of the non-RET kinases, and high rates of dose reduction and drug discontinuation. The gene discussed is RET; the disease is thyroid gland carcinoma.